GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (voxelotor) to Treat Sickle Cell Patients in EuropeGlobeNewsWire • 06/24/20
Stocks With Rising Relative Price Strength: Global Blood TherapeuticInvestors Business Daily • 06/12/20
GBT Announces Plans to Seek Expanded Labeling for Oxbryta® (voxelotor) to Treat Children Ages 4 to 11 Years with Sickle Cell DiseaseGlobeNewsWire • 06/08/20
Global Blood (GBT) Down 16.3% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/05/20
How Global Blood Therapeutics (GBT) Stock Stands Out in a Strong IndustryZacks Investment Research • 05/15/20
Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/07/20
Global Blood Therapeutics (GBT) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/06/20
Global Blood Therapeutics: Key Catalysts Remain As The Search For Clinical Benefit ContinuesSeeking Alpha • 04/20/20
GBT Commits $250,000 to Support the Sickle Cell Disease Community During COVID-19 PandemicGlobeNewsWire • 04/02/20
Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/27/20
GBT Accepting Proposals for 2020 ACCEL Grants to Support Novel Access-to-Care Programs for People Living with Sickle Cell DiseaseGlobeNewsWire • 02/20/20